Pharmidex will attend: "Advanced Therapies Integrates 2025"
December 1, 2025

📢 Pharmidex is pleased to announce that our Business Development Manager, Janette Dalay Robertson, will attend Advanced Therapies Integrates 2025


🗓 2nd December 2025

 📍 Victoria House, London


Janette Dalay Robertson looks forward to meeting industry and academic attendees to strengthen relationships and explore new collaborations that support innovation in drug discovery and development.


🤝 Let’s connect and drive the future of advanced therapies together.

Advanced Therapies Integrates

#AdvancedTherapies #Pharmidex #DrugDiscovery #Collaboration

FROM DISCOVERY TO DISTRIBUTION
April 16, 2026
Pharmidex is pleased to announce that Martin Barrett , Head of Business Development, will be attending FROM DISCOVERY TO DISTRIBUTION – Making Pharmaceuticals 2026 on 21–22 April 2026 at the Coventry Building Society Arena, UK. Martin looks forward to meeting pharma innovators, formulation scientists, manufacturing leaders and strategic partners to discuss drug discovery, development, translational science, and end-to-end pharmaceutical solutions. If you’re attending, feel free to stop by for a chat and explore how Pharmidex can support your programmes from discovery through development.
April 15, 2026
Pharmidex will be attending Swiss Biotech Day 2026 on 4–5 May 2026 at the Congress Center Basel, Switzerland. We look forward to meeting founders, investors, biotech leaders and scientific partners to discuss drug discovery, translational development and strategic R&D opportunities. Feel free to catch us for a chat!
April 9, 2026
Pharmidex partners with Data Sciences International (DSI) to utilise industry-leading whole body plethysmography (WBP) systems, incorporating the patented Halcyon® pneumotach noise suppression technology. This enables the delivery of high-quality preclinical respiratory studies with enhanced clarity, sensitivity and confidence. By leveraging the robustness of DSI’s WBP platform alongside Pharmidex’s scientific expertise, we offer well-characterised models to assess: • Cough responses • Hypercapnic challenge responses • Functional respiratory changes across disease states such as asthma This integrated approach supports reliable and translatable assessment of airway function, disease progression and therapeutic efficacy, helping to de-risk programmes and drive better decision-making in preclinical development. Always keen to hear how others are advancing respiratory endpoints in their studies.
More Posts